NYSEAMERICAN:MTNBMatinas BioPharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Matinas BioPharma Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.82 -0.03 (-3.52 %) (As of 08/14/2020 03:32 PM ET) Add Compare Share Today's Range$0.81Now: $0.82▼$0.8650-Day Range N/A52-Week Range$0.49Now: $0.82▼$2.49Volume65,016 shsAverage Volume2.44 million shsMarket Capitalization$163.10 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMatinas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.30, Matinas BioPharma has a potential upside of 295.4% from its current price of $0.83.Amount of Analyst CoverageMatinas BioPharma has only been the subject of 3 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesMatinas BioPharma has received 408 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMatinas BioPharma has received 326 “underperform” votes. (Add your “underperform” vote.)Community SentimentMatinas BioPharma has received 55.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote “Outperform” if you believe MTNB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMatinas BioPharma does not currently pay a dividend.Dividend GrowthMatinas BioPharma does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Matinas BioPharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $81,000.00 in company stock and sold $0.00 in company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.86 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:MTNB Previous Symbol CUSIPN/A CIKN/A Webwww.matinasbiopharma.com Phone+1-908-4431860Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees21 Outstanding Shares198,873,000Market Cap$163.10 million Next Earnings Date11/11/2020 (Estimated) OptionableNot Optionable $0.82 -0.03 (-3.52 %) (As of 08/14/2020 03:32 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MTNB News and Ratings via Email Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Matinas BioPharma? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Matinas BioPharma. When is Matinas BioPharma's next earnings date? Matinas BioPharma is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020. View our earnings forecast for Matinas BioPharma. How were Matinas BioPharma's earnings last quarter? Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) issued its earnings results on Monday, August, 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). View Matinas BioPharma's earnings history. What price target have analysts set for MTNB? 5 Wall Street analysts have issued twelve-month price objectives for Matinas BioPharma's shares. Their forecasts range from $3.00 to $4.00. On average, they expect Matinas BioPharma's stock price to reach $3.30 in the next year. This suggests a possible upside of 302.4% from the stock's current price. View analysts' price targets for Matinas BioPharma. What are Wall Street analysts saying about Matinas BioPharma stock? Here are some recent quotes from research analysts about Matinas BioPharma stock: 1. According to Zacks Investment Research, "Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia. " (7/14/2020) 2. HC Wainwright analysts commented, "Our price target of $4/share is based on an equally weighted composite of: (a) $2.47/share, as a 35x multiple of taxed and diluted 2033 EPS of $0.67 discounted back to 2019 at 18%; and (b) an NPV discounted cash flow between 2019-2033 of $4.81/share, with a discount rate of 12% and growth rate of 2%. These assumptions are in-line with the expected PE multiple and discount rates of an early development-stage biopharmaceutical company." (8/14/2019) Has Matinas BioPharma been receiving favorable news coverage? Headlines about MTNB stock have trended extremely negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Matinas BioPharma earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Matinas BioPharma. Are investors shorting Matinas BioPharma? Matinas BioPharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 12,730,000 shares, an increase of 18.4% from the March 15th total of 10,750,100 shares. Based on an average daily volume of 2,590,000 shares, the days-to-cover ratio is presently 4.9 days. View Matinas BioPharma's Short Interest. Who are some of Matinas BioPharma's key competitors? Some companies that are related to Matinas BioPharma include Aptose Biosciences (APS), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO), Inventiva (IVA), CEL-SCI (CVM), Pfenex (PFNX), Neptune Wellness Solutions (NEPT), IMV (IMV), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Synairgen (SNG), Ibio (IBIO) and ProMetic Life Sciences (PLI). View all competitors. What other stocks do shareholders of Matinas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Gran Tierra Energy (GTE), KushCo (KSHB), ADMA Biologics (ADMA), BioNano Genomics (BNGO), Pennsylvania R.E.I.T. (PEI), Cannabics Pharmaceuticals (CNBX), OrganiGram (OGI) and DHT (DHT). Who are Matinas BioPharma's key executives? Matinas BioPharma's management team includes the following people: Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 46, Pay $644.79k)Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 50, Pay $249.05k)Dr. Theresa Matkovits, Chief Devel. Officer (Age 53, Pay $380.62k)Dr. James J. Ferguson, Chief Medical Officer (Age 67, Pay $461.46k)Dr. Raphael J. Mannino, Chief Scientific Officer (Age 73) What is Matinas BioPharma's stock symbol? Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB." Who are Matinas BioPharma's major shareholders? Matinas BioPharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Raymond James Financial Services Advisors Inc. (0.35%), Staley Capital Advisers Inc. (0.30%), CIBC Private Wealth Group LLC (0.30%), Water Island Capital LLC (0.25%), California Public Employees Retirement System (0.18%) and Sargent Investment Group LLC (0.16%). Company insiders that own Matinas BioPharma stock include Adam K Stern, Herbert J Conrad, Jerome D Jabbour, Keith A Kucinski and Patrick G Lepore. View institutional ownership trends for Matinas BioPharma. Which institutional investors are selling Matinas BioPharma stock? MTNB stock was sold by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc.. View insider buying and selling activity for Matinas BioPharma. Which institutional investors are buying Matinas BioPharma stock? MTNB stock was purchased by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, California Public Employees Retirement System, Sargent Investment Group LLC, UBS Group AG, Staley Capital Advisers Inc., Hudson Bay Capital Management LP, MONECO Advisors LLC, and Russell Investments Group Ltd.. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, Herbert J Conrad, Jerome D Jabbour, Keith A Kucinski, and Patrick G Lepore. View insider buying and selling activity for Matinas BioPharma. How do I buy shares of Matinas BioPharma? Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Matinas BioPharma's stock price today? One share of MTNB stock can currently be purchased for approximately $0.82. How big of a company is Matinas BioPharma? Matinas BioPharma has a market capitalization of $163.10 million. Matinas BioPharma employs 21 workers across the globe. What is Matinas BioPharma's official website? The official website for Matinas BioPharma is www.matinasbiopharma.com. How can I contact Matinas BioPharma? Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860. This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
